Phase 2 N=17 Hypertonic Saline and Mucociliary Clearance in Children
Cystic Fibrosis
Primary: Percent Mucociliary Clearance at 60 Minutes — 18.6; 15.4 percentage mucociliary clearance — p=0.62
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=16 Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis
Cystic Fibrosis
Primary: Change in Average Mucociliary Clearance (0-90 Minutes) at 1 and 4 Hrs Post Dose (MCC4hr - MCCbaseline; MCC1hr - MCCbaseline) — 5.9; 6.7 Absolute % change
N/A N=12 Study of Humidified Air to Improve Mucociliary Clearance (MCC) in COPD
COPD
Primary: Mucociliary Clearance Rate - 4 Hours — 47; 56 percent clearance — p=0.11
Phase 1 N=20 Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance
Mucociliary Clearance
Primary: Mucociliary Clearance Rate -- Right Whole Lung -- Percent Particle Retention at 2 Hours (PPR2) on Day 8 — 0.94; -0.42 percent of particle retention — p=0.442
Phase 2 N=16 Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease
Cystic Fibrosis
Primary: Change in Mucociliary Clearance — 7.4; 9.5 percent clearance
Phase 4 N=14 Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis
Cystic Fibrosis
Primary: Average Rate of Mucociliary Clearance (MCC) Over 60 Minutes — 14.8 percent cleared over 60 minutes — p=0.04
N/A N=12 Study to Characterize the Durability of Hypertonic Saline to Enhance Mucociliary Clearance in Healthy Subjects
Healthy Subjects
Primary: Change in Whole Lung Mucociliary Clearance — 0.6; -4.0 % Clearance — p=<.05
Early Phase 1 N=27 Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype
Primary Ciliary Dyskinesia
Primary: Baseline MCC (Ave60Clr; Average Clearance Over 60 Minutes) — 1.4; -1.1; 7.3 percent clearance — p=0.002
Phase 2 N=38 Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection
Acute Respiratory Infection
Primary: Percent of Inhaled Radioactive Tracer Particles Cleared From Lungs — 21.4; 23.1 Percentage of inhaled radioactive tracer
Phase 4 N=12 The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis
COPD · Chronic Bronchitis · Emphysema
Primary: Difference in Mucociliary Clearance (MCC) Between Visit 1A and Visit 2A — -1.50; -0.70 percentage difference of MCC
Phase 1 N=24 Study of the Effect of HFA-152a and HFA-134a Propellants on Mucociliary Clearance in Healthy Participants
Asthma
Primary: Area Under the Percent Radiolabeled Particle Retention-time Curve up to 4 Hours [AUC(0-4h)] After Nebulized 99mTechnetium (99mTc) Inhalation on Day 7 — 351.57; 351.76…
Phase 1 N=20 Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis
Cystic Fibrosis
Primary: Absorptive Clearance Rate After Isotonic Saline Inhalation — 32.0 percent cleared / 80 minutes
N/A N=14 Prefatory Study to Explore Changes in Nasal Mucociliary Clearance and to Standardize Nasal Scraping Procedure
Smokers · Never Smokers
Primary: Saccharin Transit Time at t0, Start of Product Use — 8.4; 10.1 minutes
N/A N=24 Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics
Moderate to Severe Asthma
Primary: Change in MCC From Baseline to 7% Post Hypertonic Saline Inhalation — 29.9 percent clearance — p=<0.001
N/A N=21 Absorptive Clearance in the Cystic Fibrosis Airway
Cystic Fibrosis
Primary: Absorptive Clearance Rate — 42; 32 percentage of DTPA absoprtion per hour
N/A N=23 Effect of Hypertonic Saline on Mucus Clearance in Children Ages 5-12 With Cystic Fibrosis
Cystic Fibrosis
Primary: Change in Mucociliary Clearance Rate — 2.77; -2.35 percent clearance
Phase 3 N=485 Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis
Bronchiectasis
Primary: Rate of Graded Pulmonary Exacerbations — 1.95; 2.10; 1.69; 1.84 GPE events per year — p=0.3115
N/A N=60 Implemental Flutter Mucus Clearance Devices on Geriatric Lung Function
Pulmonary Disease
Primary: Number of Cases With Fever (Body Temperature Reach 38 Degree Celsius or Higher) — 0; 2 participants
N/A N=32 Non Invasive Ventilation as Airway Clearance in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: Lung Function: Lung Clearance Index — 9; 9.7 lung clearance index
N/A N=10 Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis
Cystic Fibrosis · Mucociliary Clearance Defect
Primary: Mucociliary Clearance-274 — 20.3; 16.8; 18.5; 19.1 percent clearance — p=0.615
Phase 4 N=50 Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
COPD · Chronic Bronchitis · Emphysema
Primary: The Primary Outcome Measure is the Rate of Exacerbations as Defined Using the Winnipeg Criteria. — 5.5; 4 exacerbations per 12 weeks
N/A N=15 Mucinex® for Treatment of Filamentary Keratitis
Filamentary Keratitis
Primary: Change in Number of Corneal Filaments — 5.8; 2.1 corneal filaments — p=<0.04
N/A N=28 ALS and Airway Clearance (ALSAC) Therapy
Amyotrophic Lateral Sclerosis · Respiratory Muscle Weakness
Primary: Respiratory Complications Severity — 8.33; 9.0; 7.8 score on a scale
Phase 4 N=552 Study to Evaluate the Safety and Tolerability of Mucinex™(Guaifenesin) 600 mg Extended-Release Bi-Layer Tablets in the Treatment of Otherwise Healthy Patients With Symptoms of Cough, Thickened Mucus and Chest Congestion
Healthy Subjects
Primary: Number of Adverse Events (AEs), Type of AE(s) and Frequency of AE(s) — 29; 0; 29; 29 Number of Events
N/A N=38 Using Rheological Methods to Characterize Cystic Fibrosis (CF) Sputum and the Effects of Mucoactive Agents
Cystic Fibrosis
Primary: Shear Rheology — 6.0; 1.8 Pascal
N/A N=25 Comparison of the Airway Clearance Efficacy of Electro Flo 5000 and the G5 Flimm-Fighter in Patients With CF
Cystic Fibrosis
Primary: Wet Sputum Weight — 5.22; 4.19 gram
Phase 2 N=378 Mucinex Exploratory Cold Study
Common Cold
Primary: Investigator's End of Study Assessment of Treatment — 163; 149 participants — p=0.0096
Phase 3 N=40 Lubiprostone and Mucus Secretion in Patients With Chronic Constipation
Constipation
Primary: Change of Mucus and Mucin Secretion in Patients With Chronic Constipation and in Controls. — 260; 133; 229; 161 mg/hour
N/A N=5 The Use of Airway Clearance Devices in ALS
Amyotrophic Lateral Sclerosis
Primary: Number of Subjects With Improved Respiratory Symptoms as Shown by Chest X-Ray Between Baseline and End of Study — 0; 0 Participants
Phase 2 N=24 Effectiveness of Pulmozyme in Infants With Cystic Fibrosis
Cystic Fibrosis
Primary: Chest CT (High Resolution Computed Tomography (HRCT) Score) — 3.7; 6.1 Score points